| Novo-Nordisk is a healthcare company focuses on diabetes care. Co. is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products and has two segments: diabetes and obesity care and biopharm. Co. has one diabetes product portfolios, including insulin, a portfolio of modern insulin and human insulin as well as a portfolio of GLP-1 receptor agonists administered both via subcutaneous injection and as a tablet. Co.'s first product to treat obesity is Saxenda®. Co.'s second obesity treatment product is Wegovy®. In addition, Co.'s marketed portfolio includes haemophilia and growth hormone therapies. We show 1 historical shares outstanding datapoints in our NVO shares outstanding history coverage, used to compute NVO market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing NVO market cap history over the course of time is important for investors
interested in comparing NVO's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of NVO versus a peer is one thing; comparing
NVO market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like NVO can fluctuate over the course of history.
With this page we aim to empower investors researching NVO by allowing them to research the NVO market cap history.